诺奖得主苏德霍夫:<br> 自然界的每一种元素对于环境而言都十分脆弱

诺奖得主苏德霍夫:
自然界的每一种元素对于环境而言都十分脆弱


Notice: Undefined index: meta_desc in /data/home/qxu1608670042/htdocs/wp-content/themes/ronghui/page-activities.php on line 164

胡祥博士:新技术永远都是先进的生产力和旧的生产关系上层建筑之间的矛盾

胡祥博士:新技术永远都是先进的生产力和旧的生产关系上层建筑之间的矛盾


Notice: Undefined index: meta_desc in /data/home/qxu1608670042/htdocs/wp-content/themes/ronghui/page-activities.php on line 164

1896

1896

The founding year – first successes

F. Hoffmann-La Roche & Co. was founded at a time when industrial revolution was changing the face of Europe. On October 1, 1896, at the age of 28, Fritz Hoffmann-La Roche launched his company as the successor company to Hoffmann, Traub & Co in Basel, Switzerland. He was among the first to recognise that the industrial manufacture of medicines would be a major advance in the fight against disease. Since then, Roche has grown into one of the world's leading healthcare companies.

1897-1914

1897-1914

Expansion and internationalisation

Roche soon expands its business activities. From 1897 to 1910, the factory in Grenzach, Germany, is enlarged and the lion’s share of manufacturing moves there. Fritz Hoffmann-La Roche and his new partner Carl Meerwein waste little time in building a network of European and overseas agents and subsidiaries. By 1914 Roche has offices in Milan, New York, St. Petersburg, and London, among others.

1928-1944

1928-1944

Vitamin boost overcomes the crisis

Roche managed to overcome the crisis under the leadership of chairman Emil C. Barell. The company experienced an unexpected upsurge spurred by its vitamin production, which made the return to former prosperity possible. Roche is able to expand once more and starts its strong commitment to the US-American market with first investments in New York and Nutley.

1945-1964

1945-1964

Streamlining and improving production

Vitamin output increases and new production locations strengthen Roche’s position as one of the main producers of vitamins. To avoid a strong dependency on vitamins, Roche intensifies pharmaceutical research. Between the early 1950s and mid-1960s pharmaceutical research is extremely diverse, with a portfolio of pharmaceuticals ranging from antidepressants and antimicrobials to agents for cancer chemotherapy. During this period, Roche’s researchers discover a compound of the benzodiazepine class that sedates without causing drowsiness.

1965-1978

1965-1978

Diversification

Propelled by the success of the benzodiazepines, Roche diversifies across the entire spectrum of healthcare. In Switzerland and the United States, bioelectronics departments are set up to develop electronic medical instruments. Rocom and Medicovision are the company’s forays into medical publishing. The acquisition of Dr. R. Maag AG, a plant protection company, reflects Roche’s growing involvement in agrochemicals. In Nutley, USA, a new diagnostics department is established.

1979-1990

1979-1990

Reform, concentration, and transparency

Roche begins to tighten its organisational structure and moves towards creating separate business units. Additionally, corporate activities are consolidated through acquisitions and divestments. After the corporate realignment, Roche operates with four core business divisions: pharmaceuticals, vitamins and fine chemicals, diagnostics, and flavours and fragrances.

1991-2000

1991-2000

International expansion and innovative developments

Through its commitment to research and innovation, Roche continues to make steady advances in drug therapy that will replace more expansive treatments and shorten hospital stays.

2000-2006

2000-2006

Company restructures to focus on biotech

Roche ranks among the world’s leading healthcare companies with its expertise in two core businesses – Diagnostics and Pharmaceuticals. Combined with its strength in biotechnology, the company paves the way to the future of healthcare with innovations in areas such as personalised healthcare.

2007-Today

2007-Today

Moving towards personalised healthcare

bet356注册验证The increased focus on innovation and biotechnology lead to important advances in diagnostic techniques and medicines aimed at molecular targets. As a result, many diseases can be detected earlier and treated more specifically. The full integration with biotech pioneer Genentech in 2009 follows acquisitions of other key players in life science research, gene sequencing and tissue diagnostics. These strengthen Roche’s access to innovation and new technologies and drive its commitment to more targeted treatments that, ultimately, make personalised healthcare a reality.